Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist
Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...
Session will be WebcastNEW YORK, June 5, 2026 /PRNewswire/ -- Mark Grant, Senior Vice President of Investor Relations and Treasurer of S&P Global (NYSE: SPGI),...
TARRYTOWN, N.Y., June 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference virtually on Monday, June 8, 2026 at 9:45 a.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the following link:
Newport Beach, CA, June 05, 2026 (GLOBE NEWSWIRE) -- Bimergen Energy Corporation [NYSE American: BESS, BESS.WS] today announced that Bob Brilon, Co-CEO will participate in The Small Cap Showcase & WTR Insights, taking place on June 9, 2026, in New York City.
The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly...
SAN FRANCISCO, June 4, 2026 /PRNewswire/ -- Prologis, Inc. (NYSE: PLD) will host a webcast and conference call with senior management to discuss its...
Files Amended Form 10 Registration StatementAnnounces Scheduling Details for Resideo and ADI Investor DaysReaffirms Previously Announced Second Quarter and Full Year 2026 Outlook; Releases...
WOKING, United Kingdom, June 4, 2026 /PRNewswire/ -- IDBS, a Danaher company and leading provider of cloud software for BioPharma organizations, today shared outcomes from...
BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).
HOUSTON, June 3, 2026 /PRNewswire/ -- EOG Resources, Inc. (EOG) is scheduled to present at the J.P. Morgan Energy, Power, Renewables and Mining Conference at...